Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment

   Recruiting · Phase 1 · Advanced Solid Tumors

   NCT07036133 · Acrotech Biopharma Inc. · 0 U.S. investigators

   $10,890research payments

2. Embody Insertional Achilles Tendinopathy

   Terminated · Insertional Achilles Tendinopathy

   NCT05998785 · Zimmer Biomet Holdings, Inc. · 0 U.S. investigators

   $10,657research payments

3. A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy

   Completed · Phase 3 · Cardiomyopathy, Hypertrophic Obstructive

   NCT05414175 · E.r. Squibb & Sons, L.l.c. · 1 U.S. investigator

   $10,545research payments

4. Prospective, Multi-center, Single-arm, Observational Study. US FDA 522 Pediatric Post Market Surveillance Study.

   Completed · Acute Kidney Injury

   NCT04608149 · Mozarc Medical US LLC · 2 U.S. investigators

   $10,489research payments

5. Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice

   Completed · Melanoma

   NCT02847728 · E.r. Squibb & Sons, L.l.c. · 6 U.S. investigators

   $10,420research payments

6. Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery

   Recruiting · Phase 1 · Brain Metastases, Adult

   NCT04689048 · Blue Earth Diagnostics · 1 U.S. investigator

   $10,333research payments

7. A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis

   Completed · Phase 3 · Eosinophilic Gastroenteritis

   NCT05214768 · E.r. Squibb & Sons, L.l.c. · 0 U.S. investigators

   $10,270research payments

8. An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting

   Withdrawn · Neovascular Age-related Macular Degeneration (nAMD)

   NCT06398080 · Regeneron Pharmaceuticals, Inc. · 5 U.S. investigators

   $10,249research payments

9. OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps

   Completed · Phase 3 · Bilateral Nasal Polyposis

   NCT03747458 · Paratek Pharmaceuticals, Inc. · 4 U.S. investigators

   $10,164research payments

10. Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy

    Active, not recruiting · Phase 3 · Prostate Cancer

    NCT05678322 · Blue Earth Diagnostics · 1 U.S. investigator

    $10,132research payments

11. A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia

    Terminated · Phase 3 · Schizophrenia

    NCT04109950 · Sumitomo Pharma America, Inc. · 1 U.S. investigator

    $10,130research payments

12. A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight

    Completed · Phase 3 · Type 2 Diabetes

    NCT04657003 · Eli Lilly and Company · 2 U.S. investigators

    $10,120research payments

13. Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

    Active, not recruiting · Phase 2 · Opioid Use Disorder (OUD)

    NCT04464980 · Indivior Inc. · 3 U.S. investigators

    $10,033research payments

14. Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

    Recruiting · Clonal Mast Cell Disease

    NCT07143669 · Sanofi US Services Inc. · 1 U.S. investigator

    $10,000research payments

15. Intravascular Ultrasound Imaging Guidance for Optimal Revascularization of Limb Arteries

    Recruiting · Not applicable · Peripheral Arterial Disease

    NCT07353905 · Philips North America LLC · 1 U.S. investigator

    $10,000research payments

16. Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease

    Active, not recruiting · Phase 2 · Alzheimer Disease, Early Onset

    NCT06268886 · E.r. Squibb & Sons, L.l.c. · 6 U.S. investigators

    $9,871research payments

17. A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants

    Completed · Phase 1 · Healthy Volunteer

    NCT06887010 · AbbVie Inc. · 0 U.S. investigators

    $9,838research payments

18. Early Angiotensin II in the Emergency Department

    Recruiting · Phase 4 · Septic Shock

    NCT06693726 · La Jolla Pharmaceutical Company · 0 U.S. investigators

    $9,820research payments

19. A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)

    Completed · Phase 1 · Healthy Volunteers

    NCT06024239 · AbbVie Inc. · 0 U.S. investigators

    $9,816research payments

20. Nasal Spray Study in Sjogren's Dry Eye Disease

    Completed · Phase 4 · Sjogren's Syndrome

    NCT05700422 · Oyster Point Pharma, Inc. · 1 U.S. investigator

    $9,800research payments

21. A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

    Recruiting · Phase 1 · Advanced Malignant Tumors

    NCT06764771 · E.r. Squibb & Sons, L.l.c. · 2 U.S. investigators

    $9,738research payments

22. Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

    Terminated · Phase 1, Phase 2 · Other Skin

    NCT03747484 · Regeneron Pharmaceuticals, Inc. · 1 U.S. investigator

    $9,712research payments

23. Treatment of Acute Ischemic Stroke With CATCHVIEW Stent Retriever in Comparison to SOLITAIRE 2/FR

    Withdrawn · Acute Ischemic Stroke

    NCT03754296 · Balt USA, LLC · 0 U.S. investigators

    $9,677research payments

24. A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

    Completed · Phase 2, Phase 3 · Ulcerative Colitis (UC)

    NCT02819635 · AbbVie Inc. · 1 U.S. investigator

    $9,675research payments

25. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous or Intravenous Doses of ABBV-701 in Healthy Adult Western and Asian Participants

    Active, not recruiting · Phase 1 · Healthy Volunteer

    NCT06895343 · AbbVie Inc. · 0 U.S. investigators

    $9,586research payments

26. Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)

    Completed · Phase 2, Phase 3 · Dermatitis, Atopic

    NCT03346434 · Regeneron Pharmaceuticals, Inc. · 0 U.S. investigators

    $9,554research payments

27. A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

    Active, not recruiting · Phase 3 · Relapsed or Refractory Multiple Myeloma

    NCT05552976 · E.r. Squibb & Sons, L.l.c. · 4 U.S. investigators

    $9,542research payments

28. A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review

    Completed · Myelofibrosis

    NCT05444972 · AbbVie Inc. · 1 U.S. investigator

    $9,500research payments

29. A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old

    Completed · Phase 1 · SARS-CoV-2

    NCT05585632 · ModernaTX, Inc. · 1 U.S. investigator

    $9,450research payments

30. Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry

    Completed · Myocardial Infarction

    NCT04076813 · Chiesi USA, Inc. · 7 U.S. investigators

    $9,400research payments

31. A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)

    Terminated · Phase 2 · Carcinoma, Non-Small-Cell Lung

    NCT05577715 · E.r. Squibb & Sons, L.l.c. · 6 U.S. investigators

    $9,350research payments

32. Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

    Completed · Phase 3 · Idiopathic Pulmonary Fibrosis

    NCT05255991 · United Therapeutics Corporation · 0 U.S. investigators

    $9,326research payments

33. A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

    Recruiting · Phase 2, Phase 3 · Metastatic Non-small Cell Lung Cancer With MTAP Deletion

    NCT07063745 · E.r. Squibb & Sons, L.l.c. · 7 U.S. investigators

    $9,307research payments

34. A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in Participants Undergoing Open Abdominal Ventral Hernia Repair for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique

    Withdrawn · Phase 2 · Ventral Hernia

    NCT05606757 · AbbVie Inc. · 1 U.S. investigator

    $9,200research payments

35. Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

    Recruiting · Phase 2 · Neuroblastoma

    NCT05489887 · Caris Mpi, Inc. · 1 U.S. investigator

    $9,100research payments

36. Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

    Recruiting · Phase 2 · Castration-Resistant Prostate Carcinoma

    NCT06632977 · Caris Mpi, Inc. · 0 U.S. investigators

    $9,100research payments

37. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

    Completed · Phase 3 · Esophageal Squamous Cell Carcinoma (ESCC)

    NCT03957590 · Beigene, Ltd. · 3 U.S. investigators

    $9,000research payments

38. A Study of LY3023414 in Participants With Advanced Cancer

    Completed · Phase 1 · Advanced Cancer

    NCT01655225 · Eli Lilly and Company · 1 U.S. investigator

    $8,977research payments

39. An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)

    Active, not recruiting · Phase 2 · Huntington Disease

    NCT06254482 · Ptc Therapeutics, Inc. · 0 U.S. investigators

    $8,850research payments

40. A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis

    Withdrawn · Phase 3 · Atopic Dermatitis

    NCT06390722 · AbbVie Inc. · 2 U.S. investigators

    $8,845research payments

41. A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia

    Completed · Phase 2 · Friedreich Ataxia

    NCT05485987 · Ptc Therapeutics, Inc. · 1 U.S. investigator

    $8,769research payments

42. Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer

    Terminated · Phase 3 · Breast Cancer

    NCT04478266 · Sanofi US Services Inc. · 2 U.S. investigators

    $8,677research payments

43. Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

    Completed · Phase 3 · Gastric, or Gastroesophageal Junction Adenocarcinoma

    NCT03777657 · Beigene, Ltd. · 1 U.S. investigator

    $8,646research payments

44. A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

    Completed · Phase 3 · Crohn's Disease

    NCT03283085 · Takeda Pharmaceuticals U.S.A., Inc. · 4 U.S. investigators

    $8,611research payments

45. A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects

    Withdrawn · Phase 1 · Opioid Withdrawal (Disorder)

    NCT06711640 · Uswm, LLC · 0 U.S. investigators

    $8,575research payments

46. A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)

    Completed · Phase 3 · Mild Cognitive Impairment (MCI)

    NCT05108922 · Eli Lilly and Company · 3 U.S. investigators

    $8,540research payments

47. A PK Study Comparing VeraCept vs. ParaGard Intrauterine Devices (IUDs)

    Completed · Phase 3 · Women at Risk for Pregnancy

    NCT03785366 · Sebela Women's Health Inc. · 1 U.S. investigator

    $8,276research payments

48. A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma

    Completed · Phase 1, Phase 2 · Soft Tissue Sarcoma

    NCT02659020 · Eli Lilly and Company · 1 U.S. investigator

    $8,142research payments

49. A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.

    Terminated · Phase 2 · Crohn's Disease

    NCT06637631 · Sanofi US Services Inc. · 0 U.S. investigators

    $8,106research payments

50. A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)

    Completed · Phase 3 · Parkinson's Disease (PD)

    NCT03781167 · AbbVie Inc. · 1 U.S. investigator

    $8,105research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.